510(k) device
BioProtect Balloon Implant System
Bioprotect, Ltd. · Hydrogel Spacer (OVB, Class II) · First FDA decision Aug 25, 2023, newest Aug 25, 2023Cancer radiation therapyProstate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
6
Naming "BioProtect"
MAUDE reports
59
Brand "BioProtect", since 2015
PubMed studies
13
Mentioning "BioProtect"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BioProtect Balloon Implant System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K222972 · Decided Aug 25, 2023 · 332 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "BioProtect", any status and sponsor, newest update first.
- Rectal Spacers Use in Prostate Cancer Radiation TherapyActive, not recruiting
Princeton ProCure management, LLC.Academic, hospital or other
NCT06594887 · 50 participants (planned) · Start Sep 6, 2024 · Primary completion Dec 2026
Device: SpaceOAR Vue; BioProtect Balloon Implant System · For: Prostate Cancer
Sites: Somerset, New Jersey
- Rectal Spacers in Prostate Cancer Patients Undergoing Radiation TherapyActive, not recruiting
Advanced Radiation Centers of New YorkAcademic, hospital or other
NCT06599476 · 150 participants (planned) · Start May 21, 2024 · Primary completion Sep 2027
Device: BioProtect Balloon Implant™ System · For: Prostate Cancer
Sites: New Hyde Park, New York
Centre Oscar LambretAcademic, hospital or other
NCT02478112 · 24 participants · Start Nov 25, 2016 · Primary completion May 28, 2018
Device: Biodegradable balloon implant · For: Prostate Cancer
Sites: Toulouse, France
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BioProtect", and for the whole product code for context.
This brand
59 reports: 4 malfunction, 55 injury, 0 death
Whole product code OVB
2,186 reports: 1,382 malfunction, 794 injury, 10 death
Newest reports for this brand
3014285231-2026-00015 · Received Sep 27, 2026 · Event dated Aug 28, 2026
Device type: Hydrogel Spacer (OVB)
Device problem as coded: Malposition of Device
Patient problem as coded: Urinary Frequency / Polyuria
3012602431-2026-00094 · Received Sep 27, 2026
Device type: Hydrogel Spacer (OVB)
Device problem as coded: Malposition of Device
Patient problem as coded: Urinary Frequency / Polyuria
3012602431-2026-00088 · Received Sep 13, 2026
Device type: Hydrogel Spacer (OVB)
Device problem as coded: Malposition of Device
Patient problem as coded: Perforation
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BioProtect"[tiab]. The summary above synthesizes these.
- Reducing the Fermentability of Wheat with a Starch Binding Agent Reduces Some of the Negative Effects of Heat Stress in Sheep.
Prathap P, Chauhan SS, Leury BJ, et al. · Animals (Basel) · 2022
- Rectal Perforation by a Balloon Spacer: A Rare Cause of Rectal Perforation Addressed Endoscopically.
Barros S, Roseira J, Caldeira P, et al. · GE Port J Gastroenterol · 2021Case Reports
- Exploring the biochemical dynamics in faba bean (Vicia faba L. minor) in response to Orobanche foetida Poir. parasitism under inoculation with different rhizobia strains.
Bouraoui M, Abbes Z, L'taief B, et al. · PLoS One · 2024Research Support, Non-U.S. Gov't
- Characterization of a new isolate of Pseudomonas fluorescens strain Psd as a potential biocontrol agent.
Upadhyay A, Srivastava S · Lett Appl Microbiol · 2008Research Support, Non-U.S. Gov't
- Assessment of Bioprotect's Biodegradable Balloon System as a Rectal Spacer in Radiotherapy: An Animal Study on Tissue Response and Biocompatibility.
Ramot Y, Levin-Harrus T, Ezratty A, et al. · Pharmaceutics · 2023
- Phenazines are involved in the antagonism of a novel subspecies of Pseudomonas chlororaphis strain S1Bt23 against Pythium ultimum.
Chi SI, Akuma M, Xu R, et al. · Sci Rep · 2024
- Long-term evaluation of the safety of a rectal-prostate spacer, the ProSpace® balloon, in patients treated with radiotherapy for prostate cancer.
Janoray G, Bruguière E, Mazurier J, et al. · BMC Cancer · 2024
- Isolation and Molecular Characterization of a Model Antagonistic Pseudomonas aeruginosa Divulging In Vitro Plant Growth Promoting Characteristics.
Uzair B, Kausar R, Bano SA, et al. · Biomed Res Int · 2018
- Comprehensive comparison of Bioprotect balloon and Barrigel hydrogel rectal spacers in proton therapy for prostate cancer.
Arnold J · BMC Urol · 2026Comparative Study
- Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe Traumatic Brain Injury Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III Trial.
Korley F, Pauls Q, Yeatts SD, et al. · J Neurotrauma · 2021Clinical Trial, Phase III, Multicenter Study
- BioPro-RCMI-1505 trial: multicenter study evaluating the use of a biodegradable balloon for the treatment of intermediate risk prostate cancer by intensity modulated radiotherapy; study protocol.
Pasquier D, Bogart E, Bonodeau F, et al. · BMC Cancer · 2018Clinical Trial Protocol
- Traumatic Brain Injury Severity Measured by Clinical, Radiographical, and Blood Biomarker Measures Is Associated with Non-Neurological Organ Dysfunction: A Secondary Analysis of ProTECT III and Bio-ProTECT.
Barton DJ, Fan EK, Gober IG, et al. · J Neurotrauma · 2025Randomized Controlled Trial
Other devices of this type
Also filed under product code OVB.
- SpaceOAR SystemAugmenix, Inc. · De Novo 2018
- SpaceOAR Flex SystemBoston Scientific Corporation · 510(k) 2026
- SpaceOAR Vue System (SV-2101)Boston Scientific Corporation · 510(k) 2026
- Barrigel Injectable GelPalette Life Sciences · 510(k) 2022
- SpaceOAR SystemBoston Scientific Corporation · 510(k) 2020
- SpaceOAR Vue HydrogelAugmenix, Inc. · 510(k) 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.